Clinical Trial

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated December 24, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-01; most recent amendment 2025-04-28.
Status change: Not Yet Recruiting → Recruiting 2023-11-19
Trial Details
NCT Number NCT06030258
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 120 participants
Start Date 2023-10-30
Primary Completion 2025-12-24 (estimated)
Study Completion 2025-12-24 (estimated)
Updated on ClinicalTrials.gov 2025-04-30